http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0208235-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_746624be7865f5426024f9852dee6144 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_796271cb56b52651a027e2cd127b661c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5024edf3408bb8e79210526d860880f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5dceb2e544e00cc5890d213cde6d99c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b740dea29493a833b5f3cf5b140569c0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-683 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4084 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-683 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-40 |
| filingDate | 2001-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d9322194aa16bb9ce130aa65fe8b344 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_586ef9eb3a50c6e982eef231f0399760 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36846e28937d651d23037f74b28403ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddb4af73f6505f4172fe8f84c9aad866 |
| publicationDate | 2002-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0208235-A1 |
| titleOfInvention | Medicament for oral application, containing aminopropyl phosphonic acid esters as an active ingredient |
| abstract | The pharmaceutical agents, aminopropyl phosphonic acids, such as 3-N-formyl hydroxyl aminopropyl phosphonic acid (fosmidomycin) and 3-N-acetyl hydroxyl aminopropyl phosphonic acid (FR900098), comprising highly polar functional groups, exhibit insufficient resorption power in the gastrointestinal tract. However, many esters of said active ingredients prove to be suitable prodrugs, for example the compounds of formula (I) wherein R1 and R2 are independently selected from the group consisting of hydrogen and C1-9-alkyl; R3 is selected from the group consisting of substituted and unsubstituted phenyl esters and R5-Y-R6; R4 is selected from the group consisting of substituted and unsubstituted phenyl esters and R7-X-R8; X and Y are independently selected from the group consisting of sulphur and oxygen; R7 and R5 are independently selected from the group consisting of C1-9-alkylene groups and C0-9-alkyl-ar-C0-9-alkyl groups; and R6 and R8 are independently selected from the group consisting of C1-9-alkylene groups and ar-C1-9-alkylene groups; or R3 and R4 together form an alkylene group comprising 1 to 5 carbon atoms, said group bonding the two ester-forming oxygen atoms of the phosphorus group together in such a way that a ring is formed. Said compounds are sufficiently stable to be able to stay in the gastrointestinal tract without considerably decomposing, but do decompose to a large extent in the target cell. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020008189-A1 |
| priorityDate | 2000-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.